Cytek Biosciences, Inc. has completed an IPO in the amount of $247.598795 million.
July 22, 2021 at 05:00 am
Share
Cytek Biosciences, Inc. has completed an IPO in the amount of $247.598795 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 14,564,635
PriceRange: $17
Discount Per Security: $1.19
Transaction Features: Reserved Share Offering; Sponsor Backed Offering
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.